FDA Issues Safety Communication for Fluoroquinolone Antibiotics

Published: 12/21/2018

  • Food and Drug Administration
Relevant To:
  • Medical Office,
  • Critical Access Hospitals,
  • Hospitals,
  • Long Term Care,
  • Ambulatory Care

The U.S Food and Drug Administration (FDA) has issued a safety communication for Fluoroquinolone Antibiotics. An FDA review has revealed that fluoroquinolone antibiotics can increase the occurrence of rare but serious events of ruptures or tears in the aorta. Aortic dissections, or ruptures of an aortic aneurysm can lead to dangerous bleeding or even death. They can occur with fluoroquinolones for systemic use given by mouth or through an injection.

FDA Recommendations: Healthcare professional

Sign Up for Free Trial